{"disease":{"id":"tirumotecan","name":"tirumotecan"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07511023","title":"Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07438626","title":"Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}